BioVie Inc. (BIVI) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
BioVie Inc.
Address
680 West Nye Lane
Carson City, NV 89703
United States of America (the)
Phone
775 888 3162
Website
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
September 18, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Cuong Viet Do | President, Chief Executive Officer & Director | 736,000 | 1966 |
| Joanne Wendy Kim | Chief Financial Officer, Treasurer & Corporate Secretary | 389,375 | 1956 |
| Joseph Palumbo | Executive Vice President of R&D and Chief Medical Officer | 645,250 | 1961 |
| Penelope Markham | Senior Vice President of Liver Disease & Long COVID Programs | 0 | 1966 |
| Denise Smith | Senior Vice President of Manufacturing & Development | 0 | N/A |
| Clarence N. Ahlem | Senior Vice President of Operations | 0 | 1956 |
| David Morse | Senior Vice President & Chief Regulatory Officer | 0 | N/A |
| Christopher L. Reading | Senior Vice President of Alzheimer's Disease Program | 0 | 1948 |
Description
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
